IDEXX Laboratories (NASDAQ:IDXX) Issues FY 2026 Earnings Guidance

IDEXX Laboratories (NASDAQ:IDXX) updated its FY 2026 earnings guidance on Tuesday. The company provided EPS guidance of 14.690-14.940 for the period, compared to the consensus earnings per share estimate of 14.640. The company issued revenue guidance of $4.7 billion-$4.7 billion, compared to the consensus revenue estimate of $4.7 billion.

IDEXX Laboratories Trading Up 3.8%

IDEXX Laboratories stock traded up $21.82 during trading hours on Tuesday, hitting $589.66. The stock had a trading volume of 373,352 shares, compared to its average volume of 577,157. The business’s 50 day simple moving average is $557.53 and its 200-day simple moving average is $588.43. IDEXX Laboratories has a one year low of $518.55 and a one year high of $769.98. The stock has a market cap of $46.51 billion, a price-to-earnings ratio of 43.62, a P/E/G ratio of 3.06 and a beta of 1.54. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Tuesday, August 4th. The company reported $4.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.94 by $0.33. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.IDEXX Laboratories’s revenue was up 9.7% on a year-over-year basis. During the same period in the prior year, the company earned $3.50 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. On average, equities analysts predict that IDEXX Laboratories will post 14.68 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. Wall Street Zen downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. UBS Group decreased their price objective on IDEXX Laboratories from $640.00 to $620.00 and set a “neutral” rating for the company in a report on Monday, July 27th. Citigroup assumed coverage on IDEXX Laboratories in a research report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 target price for the company. Finally, Weiss Ratings raised IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a report on Wednesday, July 29th. Six research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, IDEXX Laboratories currently has an average rating of “Moderate Buy” and an average target price of $749.00.

Hedge Funds Weigh In On IDEXX Laboratories

A number of hedge funds have recently bought and sold shares of the company. Sivia Capital Partners LLC bought a new position in IDEXX Laboratories in the second quarter worth approximately $265,000. DV Equities LLC acquired a new position in shares of IDEXX Laboratories during the fourth quarter worth approximately $76,000. Greenline Wealth Management LLC acquired a new position in shares of IDEXX Laboratories during the fourth quarter worth approximately $68,000. Navera Investment Management Ltd. bought a new position in shares of IDEXX Laboratories in the 4th quarter worth $139,000. Finally, Meeder Asset Management Inc. lifted its holdings in shares of IDEXX Laboratories by 563.2% in the 4th quarter. Meeder Asset Management Inc. now owns 126 shares of the company’s stock worth $85,000 after purchasing an additional 107 shares in the last quarter. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.